Osteosarcoma treatment - Where do we stand? A state of the art review

被引：1052

作者：

Luetke, Anja ^{[1
]}

Meyers, Paul A. ^{[2
]}

Lewis, Ian ^{[3
]}

Juergens, Heribert ^{[1
]}

机构：

[1] Univ Childrens Hosp Munster, D-48149 Munster, Germany

[2] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA

[3] Alder Hey Childrens NHS FT, Liverpool, Merseyside, England

来源：

CANCER TREATMENT REVIEWS | 2014年 / 40卷 / 04期

关键词：

Osteosarcoma; Systemic treatment; Outcome; Prognostic factors; Metastatic disease; Mifamurtide; Interferon alpha; HIGH-GRADE OSTEOSARCOMA; HIGH-DOSE METHOTREXATE; ITALIAN-SARCOMA-GROUP; PROGNOSTIC-FACTORS; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; NONMETASTATIC OSTEOSARCOMA; PREOPERATIVE CHEMOTHERAPY; LOCALIZED OSTEOSARCOMA; OPERABLE OSTEOSARCOMA;

D O I：

10.1016/j.ctrv.2013.11.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Long-term outcome for patients with high-grade osteosarcoma has improved with the addition of systemic chemotherapy, but subsequent progress has been less marked. Modern, multiagent, dose-intensive chemotherapy in conjunction with surgery achieves a 5-year event-free survival of 60-70% in extremity localized, non-metastatic disease. A major, as yet unsolved, problem is the poor prognosis for metastatic relapse or recurrence, and for patients with axial disease. This article reviews the current state of the art of systemic osteosarcoma therapy by focusing on the experiences of cooperative osteosarcoma groups. Also, we shed light on questions and challenges posed by the aggressiveness of the tumor, and we consider potential future directions that may be critical to progress in the prognosis of high-grade osteosarcoma. (C) 2014 Published by Elsevier Ltd.

引用

页码：523 / 532

页数：10

共 97 条

[1]

Anderson PM, 2013, PEDIAT BLOOD CANC, DOI DOI 10.1002/PBC

[2] The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1355 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols [J].

Andreou, D. ;

Bielack, S. S. ;

Carrle, D. ;

Kevric, M. ;

Kotz, R. ;

Winkelmann, W. ;

Jundt, G. ;

Werner, M. ;

Fehlberg, S. ;

Kager, L. ;

Kuehne, T. ;

Lang, S. ;

Dominkus, M. ;

Exner, G. U. ;

Hardes, J. ;

Hillmann, A. ;

Ewerbeck, V. ;

Heise, U. ;

Reichardt, P. ;

Tunn, P. -U. .

ANNALS OF ONCOLOGY, 2011, 22 (05) :1228-1235

[3] Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? [J].

Anninga, Jakob K. ;

Gelderblom, Hans ;

Fiocco, Marta ;

Kroep, Judith R. ;

Taminiau, Anstoni H. M. ;

Hogendoorn, Pancras C. W. ;

Egeler, R. Maarten .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (16) :2431-2445

[4] Second malignant neoplasms in long-term survivors of osteosarcoma - Memorial sloan-kettering cancer center experience [J].

Aung, L ;

Gorlick, RG ;

Shi, W ;

Thaler, H ;

Shorter, NA ;

Healey, JH ;

Huvos, AG ;

Meyers, PA .

CANCER, 2002, 95 (08) :1728-1734

[5] Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy - 15-year experience in 789 patients treated at a single institution [J].

Bacci, G ;

Longhi, A ;

Versari, M ;

Mercuri, M ;

Briccoli, A ;

Picci, P .

CANCER, 2006, 106 (05) :1154-1161

[6] Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide [J].

Bacci, G ;

Briccoli, A ;

Rocca, M ;

Ferrari, S ;

Donati, D ;

Longhi, A ;

Bertoni, F ;

Bacchini, P ;

Giacomini, S ;

Forni, C ;

Manfrini, M ;

Galletti, S .

ANNALS OF ONCOLOGY, 2003, 14 (07) :1126-1134

[7] Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol [J].

Bacci, G ;

Briccoli, A ;

Ferrari, S ;

Longhi, A ;

Mercuri, M ;

Capanna, R ;

Donati, D ;

Lari, S ;

Forni, C ;

DePaolis, M .

EUROPEAN JOURNAL OF CANCER, 2001, 37 (16) :2030-2039

[8] Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli Osteosarcoma-2 protocol: An updated report [J].

Bacci, G ;

Ferrari, S ;

Bertoni, F ;

Ruggieri, P ;

Picci, P ;

Longhi, A ;

Casadei, R ;

Fabbri, N ;

Forni, C ;

Versari, M ;

Campanacci, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) :4016-4027

[9] High Grade Osteosarcoma of the Extremities With Lung Metastases at Presentation: Treatment With Neoadjuvant Chemotherapy and Simultaneous Resection of Primary and Metastatic Lesions [J].

Bacci, Gaetano ;

Rocca, Michele ;

Salone, Mariacristina ;

Balladelli, Alba ;

Ferrari, Stefano ;

Palmerini, Emanuela ;

Forni, Cristiana ;

Briccoli, Antonio .

JOURNAL OF SURGICAL ONCOLOGY, 2008, 98 (06) :415-420

[10] Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy - The Rizzoli experience in 52 patients [J].

Bacci, Gaetano ;

Longhi, Alessandra ;

Bertoni, Franco ;

Briccoli, Antonio ;

Versari, Michela ;

Pignotti, Elettra ;

Picci, Piero .

ACTA ORTHOPAEDICA, 2006, 77 (06) :938-943

← 1 2 3 4 5 6 7 8 9 10 →